Bayer Avelox Cardiac Safety Studies Recommended By FDA Committee
Executive Summary
Cardiac QT prolongation associated with Bayer's fluoroquinolone Avelox (moxifloxacin) should be evaluated in high risk patients, FDA's Anti-Infective Drugs Advisory Committee concluded Oct. 21.
You may also be interested in...
Bayer Avelox Skin Infection Indication "Approvable"; Needs More Safety Data
Bayer's Avelox (moxifloxacin) is "approvable" for the treatment of uncomplicated skin and skin structure infections, FDA said in a Dec. 10 letter granting the antibiotic approval for three other indications.
Bayer Avelox Skin Infection Indication "Approvable"; Needs More Safety Data
Bayer's Avelox (moxifloxacin) is "approvable" for the treatment of uncomplicated skin and skin structure infections, FDA said in a Dec. 10 letter granting the antibiotic approval for three other indications.
FDA/PhRMA Task Force To Assess QT Risk By Preclinical Markers
FDA and the Pharmaceutical Research & Manufacturers of America are forming a joint task force to define a preclinical threshold to serve as a predictor for the risk of drug-associated QT prolongation.